Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Health Security

    PharmAthene Receives 5M Initial Payment from SIGA

    By Global Biodefense StaffApril 13, 2016
    Biodefense and Health Security Industry News
    Share
    Facebook LinkedIn Reddit Email

    Biodefense and Health Security Industry NewsPharmAthene, Inc., a biodefense company engaged in the development of next generation medical countermeasures against biological and chemical threats, reported today that the U.S. Bankruptcy Court for the Southern District of New York approved a reorganization plan that lays out the terms and conditions under which SIGA Technologies, Inc. will exit from bankruptcy, effective April 12, 2016.

    The plan was negotiated between SIGA and the Statutory Creditor’s Committee of which PharmAthene is a member. PharmAthene has received a $5 million initial payment from SIGA. The payment is creditable against final satisfaction of PharmAthene’s claim of approximately $205 million plus interest and is not refundable.

    Under the plan, PharmAthene’s judgment will be satisfied no later than October 20, 2016 by SIGA in one of the following ways, to be chosen by SIGA:

    • Payment in full in cash of the unpaid balance plus interest that will accrue at 8.75% after Plan approval; or
    • Delivery to PharmAthene of 100% of SIGA’s common stock; or
    • Such other treatment as may be mutually agreed upon by SIGA and PharmAthene and approved by the Court

    The dispute and settlement dates back to a merger agreement between the two companies. When SIGA withdrew from the agreement, PharmAthene sued over rights to the anti-smallpox drug, ST-246, a countermeasure funded heavily by the Biomedical Advanced Research and Development Authority (BARDA).

    In the event that SIGA pays PharmAthene cash in full and barring any unexpected material events, PharmAthene currently expects that it will distribute at least 90% of the after tax net cash proceeds to its shareholders.

    The timing and form of distribution will depend upon PharmAthene’s analysis of its current situation, applicable corporate statutes related to distributions and the economic consequences to its shareholders of any such distribution.

    In addition to the distribution of these cash proceeds, PharmAthene intends to seek M&A or other partnering transactions to maximize the value of its remaining assets and anthrax vaccine programs.

    PharmAthene also stated they will work to develop a transition plan for managing and operating SIGA as a separate business in the event SIGA decides to satisfy the judgment by delivering 100% of SIGA’s stock to PharmAthene.

    Anthrax ASPR BARDA Bioterrorism HHS Poxviruses Smallpox
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleThe DoD and Synthetic Biology Milestones
    Next Article USAID Global Health 2016 BAA

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.